SPTBN2

Across TCGA pan-cancer cohorts, SPTBN2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPTBN2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPTBN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPTBN2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

HNSC, BLCA, and UCEC are the cancer types where SPTBN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.125	0.715	<.001	24	view →
BLCA	DFS	Median	All	0.881	0.604	.013	11	view →
UCEC	DFS	Median	All	0.793	0.623	.009	10	view →
KIRP	OS	Median	II,III,IV	0.188	0.771	.016	9	view →
PRAD	DFS	Median	All	0.617	0.886	.043	6	view →
SKCM	OS	Median	All	0.687	0.791	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPTBN2–HNSC (OS)

Open the HNSC breakdown →